Millennium Management
ARQT icon

Millennium Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Millennium Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-11,600
Closed -$61.6K – 6061
2023
Q3 		$61.6K Hold
11,600
– – ﹤0.01% 5443
2023
Q2 		$111K Buy
+11,600
New +$129K ﹤0.01% 5306

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management's ARQT Position: Q1 2026 in Review

Millennium Management reduced its Arcutis Biotherapeutics (ARQT) stake by 79% in Q1 2026, selling an estimated $4.78M and leaving 49,333 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #4283.

Millennium Management first reported a position in ARQT in Q1 2020 and has held it in 20 quarters since. The position peaked at $32.2M in Q4 2024. 269 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Millennium Management held 49,333 shares of Arcutis Biotherapeutics worth $1.16M as of Q1 2026.
  • Millennium Management sold 187,437 Arcutis Biotherapeutics shares in Q1 2026, an estimated $4.78M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #4283 holding.
  • Millennium Management first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 20 quarters since.
  • Millennium Management's Arcutis Biotherapeutics position peaked at $32.2M in Q4 2024.
  • 269 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.